Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Outpatient Department, West China Hospital, Sichuan University/West China School of Nusing Sichuan University, Chengdu, China.
Pathol Oncol Res. 2023 Apr 24;29:1611055. doi: 10.3389/pore.2023.1611055. eCollection 2023.
The association between pretreatment skeletal muscle index (SMI) and long-term survival of gastric cancer patients remains unclear up to now. The aim of this meta-analysis was to identify the prognostic value of pretreatment SMI in gastric cancer. The PubMed, EMBASE and Web of Science electronic databases were searched up to 5 June 2022 for relevant studies. The primary outcome was overall survival (OS) and the second outcomes were disease-free survival (DFS) and cancer-specific survival (CSS). The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to assess the relationship between pretreatment SMI and survival of gastric cancer patients. All statistical analyses were conducted by STATA 15.0 software. A total of 31 retrospective studies involving 12,434 patients were enrolled in this meta-analysis. The pooled results demonstrated that lower pretreatment was significantly associated with poorer OS (HR = 1.53, < 0.001). Besides, lower pretreatment SMI was also related with worse DFS (HR = 1.39, < 0.001) and CSS (HR = 1.96, < 0.001). Pretreatment SMI was significantly associated with prognosis of gastric cancer patients and lower SMI predicted worse survival. However, more prospective high-quality studies are still needed to verify our findings.
目前，术前骨骼肌指数（SMI）与胃癌患者长期生存之间的关系尚不清楚。本荟萃分析的目的是确定术前 SMI 在胃癌中的预后价值。检索了 PubMed、EMBASE 和 Web of Science 电子数据库，截至 2022 年 6 月 5 日，以获取相关研究。主要结局指标是总生存（OS），次要结局指标是无病生存（DFS）和癌症特异性生存（CSS）。使用 STATA 15.0 软件组合风险比（HR）和 95%置信区间（CI）来评估术前 SMI 与胃癌患者生存之间的关系。这项荟萃分析共纳入了 31 项回顾性研究，涉及 12434 名患者。汇总结果表明，术前 SMI 较低与 OS 较差显著相关（HR = 1.53，<0.001）。此外，术前 SMI 较低还与 DFS（HR = 1.39，<0.001）和 CSS（HR = 1.96，<0.001）较差相关。术前 SMI 与胃癌患者的预后显著相关，较低的 SMI 预示着更差的生存。然而，仍需要更多前瞻性高质量研究来验证我们的发现。
